• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Tessa Receives PRIME Designation from EMA for CD30 CAR-T Therapy americanpharmaceuticalreview
    January 27, 2021
    Tessa Therapeutics announced the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
  • Tessa Therapeutics Appoints CCO contractpharma
    July 24, 2017
    Butler brings 20 years of pharma/biopharma experience across several therapeutic areas

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service